Akebia Therapeutics Inc. buy BTIG Research
Start price
29.10.25
/
50%
€1.93
Target price
29.10.26
€4.29
Performance (%)
-44.11%
Price
29.07.26
€1.09
Summary
This prediction is currently active. Massive losses of -44.11% have been the result for the BUY prediction by BTIG_Research. This prediction currently runs until 29.10.26. The prediction end date can be changed by BTIG_Research at any time. BTIG_Research has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Akebia Therapeutics Inc. | -1.452% | -1.452% |
| iShares Core DAX® | 1,01 % | 2,70 % |
| iShares Nasdaq 100 | -6,47 % | -8,77 % |
| iShares Nikkei 225® | -6,52 % | -12,58 % |
| iShares S&P 500 | -2,72 % | -1,75 % |
Comments by BTIG_Research for this prediction
In the thread Akebia Therapeutics Inc. diskutieren
Akebia Therapeutics (NASDAQ:AKBA) had its price target lowered by analysts at BTIG Research from $10.00 to $5.00. They now have a "buy" rating on the stock.
Ratings data for AKBA provided by MarketBeat
Stopped prediction by BTIG_Research for Akebia Therapeutics Inc.
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.18
07.04.26
07.04.26
€3.47
07.04.27
07.04.27
-7.65%
29.07.26
29.07.26
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.08
25.02.26
25.02.26
€3.39
25.02.27
25.02.27
0.14%
29.07.26
29.07.26
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.27
02.12.25
02.12.25
€4.31
02.12.26
02.12.26
-15.42%
29.07.26
29.07.26
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€0.92
29.11.23
29.11.23
€3.64
29.11.24
29.11.24
122.78%
30.11.24
30.11.24